New combo therapy aims to boost bladder cancer treatment before surgery
NCT ID NCT07440901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with muscle-invasive bladder cancer. About 30 participants will receive the combination therapy, and researchers will monitor how the tumor and immune system respond. The goal is to find better ways to predict and enhance treatment success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab combined with chemotherapy (GC regimen)
What this could lead to
If successful, this could lead to a more effective neoadjuvant treatment approach for muscle-invasive bladder cancer, potentially improving outcomes before surgery.
What could go wrong
This is an early exploratory study with only 30 participants, so results may not apply broadly. The combination therapy may also cause side effects like immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••